4-phenylbutyric acid has been researched along with Koch's Disease in 2 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mily, A | 1 |
| Rekha, RS | 1 |
| Kamal, SM | 1 |
| Akhtar, E | 1 |
| Sarker, P | 1 |
| Rahim, Z | 1 |
| Gudmundsson, GH | 1 |
| Agerberth, B | 1 |
| Raqib, R | 1 |
| Coussens, AK | 1 |
| Wilkinson, RJ | 1 |
| Martineau, AR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial of Oral Phenylbutyrate and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis in Bangladesh: a Pilot Study[NCT01580007] | Phase 2 | 288 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for 4-phenylbutyric acid and Koch's Disease
| Article | Year |
|---|---|
Oral intake of phenylbutyrate with or without vitamin D3 upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Antimicrobial Cationic Peptides; Antineoplastic Agents; Cal | 2013 |
1 other study available for 4-phenylbutyric acid and Koch's Disease
| Article | Year |
|---|---|
Phenylbutyrate Is Bacteriostatic against Mycobacterium tuberculosis and Regulates the Macrophage Response to Infection, Synergistically with 25-Hydroxy-Vitamin D3.
Topics: Anti-Bacterial Agents; Calcifediol; Cell Proliferation; Drug Synergism; Flow Cytometry; Humans; Macr | 2015 |